Based on preclinical and clinical evidence of an antifibrotic mechanism, two Phase 3 randomized trials of treprostinil as inhaled prescription therapy were conducted for treatment of idiopathic pulmonary fibrosis (IPF). The publication reports the results of the double-blind TETON 1 trial, in which patients with IPF were randomly assigned the inhalation of the experimental drug…
DetailsThe PHINDER trial is a real-time, collaborative study across many medical centers to improve non-invasive methods of screening for pulmonary hypertension, or PH (dangerously high blood pressure in the lungs), that affects patients with chronic lung scarring disease. The preliminary analysis took data from an initial group of 190 enrolled patients with interstitial lung disease,…
Details
The Pulmonix team proudly attended the Triad Business Journal “Best Places to Work” gala, where we were recognized as a finalist for one of the Triad’s top workplaces. This honor reflects the collaborative spirit, dedication, and passion that our team brings to advancing rare disease research every day. At Pulmonix, we lead with a patient-first mindset and…
Details
The Pulmonix team, in partnership with Cone Health, spent the day volunteering with The Kellin Foundation in Greensboro to help combat food insecurity. Together, our staff packaged nutritious food for 100 families, providing essential provisions and a message of hope to those in need. This meaningful experience was a reminder of the importance of giving…
Details